{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:53:37Z","timestamp":1776333217722,"version":"3.51.2"},"reference-count":74,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>The treatment paradigm for HER2-positive metastatic breast cancer has evolved from continuous chemotherapy-based regimens to a model of finite chemotherapy induction followed by sustained antibody-driven disease control. The CLEOPATRA trial established dual HER2 blockade with trastuzumab and pertuzumab plus a taxane as the biological and clinical anchor of this approach, demonstrating that chemotherapy is administered for a defined induction period, after which antibody maintains disease suppression. An increasing body of clinical evidence indicates that antibody-based regimens can be combined with targeted agents, including CDK4\/6 inhibitors or HER2 tyrosine kinase inhibitors, to achieve durable disease control without the need for continuous chemotherapy. In the PATINA trial, the addition of palbociclib to trastuzumab, pertuzumab, and endocrine therapy was associated with a clinically meaningful improvement in progression-free survival in hormone receptor-positive, HER2-positive metastatic breast cancer. At the same time, quality of life was maintained despite higher rates of hematologic toxicity. More recently, HER2-CLIMB-05 demonstrated that the addition of tucatinib to dual HER2 antibody therapy significantly prolonged progression-free survival, supporting a model of sustained, multi-agent HER2 pathway suppression. The monarcHER trial provided biological proof of concept that antibody plus CDK4\/6 inhibition can achieve disease control without chemotherapy in hormone receptor-positive, HER2-positive disease. Collectively, these advances support a translational framework in which antibody therapy serves as a central component of treatment strategies, with targeted partners selected according to tumor biology and prior therapy. This review summarizes the biological basis, clinical evidence, and future perspectives of antibody-driven maintenance in HER2-positive metastatic breast cancer.<\/jats:p>","DOI":"10.3390\/antib15020036","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:04:42Z","timestamp":1776330282000},"page":"36","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-Chemotherapy Antibody-Based Continuation and Maintenance Strategies in HER2-Positive Metastatic Breast Cancer: A Translational Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-711X","authenticated-orcid":false,"given":"Katarzyna","family":"Pogoda","sequence":"first","affiliation":[{"name":"Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Lewi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2223-644X","authenticated-orcid":false,"given":"Paulina","family":"Kalman","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, 02781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2592-9946","authenticated-orcid":false,"given":"Anna","family":"Ba\u0142ata","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5278","authenticated-orcid":false,"given":"Piotr J.","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jagiellonian University-Medical College, 31-501 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/annonc\/mdx406","article-title":"Effect of docetaxel duration on clinical outcomes: Exploratory analysis of CLEOPATRA, a phase III randomized controlled trial","volume":"28","author":"Miles","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1078-0432.CCR-22-1092","article-title":"Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis","volume":"29","author":"Arpino","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","article-title":"Management of patients with advanced-stage HER2-positive breast cancer: Current evidence and future perspectives","volume":"21","author":"Marra","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13058-016-0773-6","article-title":"Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results","volume":"18","author":"Perez","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and Future Management of HER2-Positive Metastatic Breast Cancer","volume":"17","author":"Prat","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_10","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s11864-024-01277-2","article-title":"Updates in Treatment of HER2-positive Metastatic Breast Cancer","volume":"25","author":"Avelino","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nabieva, N., and Fasching, P.A. (2023). CDK4\/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15061763"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dieras, V., Curigliano, G., Martin, M., Lerebours, F., Tsurutani, J., Savard, M.F., Jerzak, K.J., Hu, X., Martins de Aquino Pimentel, L.C., and O\u2019Sullivan, C.C. (2025). HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., JCO2502600.","DOI":"10.1200\/JCO-25-02600"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","article-title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial","volume":"21","author":"Tolaney","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa2511218","article-title":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","volume":"394","author":"Metzger","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"RF4-02","DOI":"10.1158\/1557-3265.SABCS25-RF4-02","article-title":"Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer","volume":"32","author":"Janni","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: The complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000354253","article-title":"Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications","volume":"8","author":"Giuliano","year":"2013","journal-title":"Breast Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc2933","article-title":"Does tumour dormancy offer a therapeutic target?","volume":"10","author":"Goss","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2010.03.004","article-title":"Molecular mechanisms underlying tumor dormancy","volume":"294","author":"Almog","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1535-6108(02)00212-X","article-title":"Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis","volume":"2","author":"Moody","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrc1370","article-title":"Dissecting the metastatic cascade","volume":"4","author":"Pantel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s41669-024-00478-7","article-title":"A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab","volume":"8","author":"Khoirunnisa","year":"2024","journal-title":"PharmacoEconomics\u2014Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/annonc\/mdq585","article-title":"Fc\u03b3R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer","volume":"22","author":"Tamura","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","article-title":"Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era","volume":"60","author":"Rivero","year":"2021","journal-title":"Breast"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e003171","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/j.annonc.2025.08.909","article-title":"485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+\/HER2+ metastatic breast cancer (MBC)","volume":"36","author":"Mazza","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: A model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"105572","DOI":"10.1016\/j.esmoop.2025.105572","article-title":"Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: Final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial","volume":"10","author":"Pascual","year":"2025","journal-title":"ESMO Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.annonc.2025.10.016","article-title":"Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive\/HER2-positive early breast cancer: Primary results from the randomized phase II TOUCH trial (IBCSG 55-17)","volume":"37","author":"Malorni","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1078-0432.CCR-23-1209","article-title":"Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients","volume":"30","author":"Tolaney","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Perou","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","article-title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1200\/JCO.22.02511","article-title":"Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes","volume":"41","author":"Parker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gao, Y., Yu, Y., Zhang, M., Yu, W., and Kang, L. (2024). Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1448687"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergen.2025.08.010","article-title":"Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration","volume":"298\u2013299","author":"Ubaid","year":"2025","journal-title":"Cancer Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/1354750X.2025.2591717","article-title":"Emerging biomarkers in breast cancer: Translational and multi-omics perspectives in precision oncology","volume":"30","author":"Yasmin","year":"2025","journal-title":"Biomarkers"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"dju152","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","article-title":"Deconstructing the molecular portraits of breast cancer","volume":"5","author":"Prat","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"73362","DOI":"10.18632\/oncotarget.20629","article-title":"Intrinsic molecular subtypes of HER2+ breast cancer","volume":"8","author":"Prat","year":"2017","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-011-1572-5","article-title":"Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer","volume":"128","author":"Razis","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from SOLAR-1","volume":"32","author":"Ciruelos","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-017-4596-7","article-title":"Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy","volume":"168","author":"Pistilli","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"RF02-01","DOI":"10.1158\/1538-7445.SABCS23-RF02-01","article-title":"Abstract RF02-01: A Multicenter, Phase I\/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE)","volume":"84","author":"Patel","year":"2024","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Hurvitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-026-07936-2","article-title":"Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2\u2009+\u2009breast cancer","volume":"216","author":"Song","year":"2026","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1634\/theoncologist.2010-0360","article-title":"Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: Should we practice ahead of the evidence?","volume":"16","author":"Wong","year":"2011","journal-title":"Oncologist"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Balata, A., and Pogoda, K. (2025). Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. Antibodies, 15.","DOI":"10.3390\/antib15010003"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study","volume":"23","author":"Beeram","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"LBO1-04","DOI":"10.1158\/1538-7445.SABCS23-LBO1-04","article-title":"Abstract LBO1-04: Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+\/HR+ metastatic breast cancer (mBC)","volume":"84","author":"Cejalvo","year":"2024","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","volume":"394","author":"Tolaney","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Singh, D.D., Lee, H.J., and Yadav, D.K. (2022). Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1089066"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With \u22652 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2023.02.002","article-title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"184","author":"Holmes","year":"2023","journal-title":"Eur. J. Cancer"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/2\/36\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:11:49Z","timestamp":1776330709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/2\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["antib15020036"],"URL":"https:\/\/doi.org\/10.3390\/antib15020036","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}